[go: up one dir, main page]

CY1118154T1 - Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη - Google Patents

Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη

Info

Publication number
CY1118154T1
CY1118154T1 CY20151100674T CY151100674T CY1118154T1 CY 1118154 T1 CY1118154 T1 CY 1118154T1 CY 20151100674 T CY20151100674 T CY 20151100674T CY 151100674 T CY151100674 T CY 151100674T CY 1118154 T1 CY1118154 T1 CY 1118154T1
Authority
CY
Cyprus
Prior art keywords
active substance
therapeutic system
interderative
administration
buprenorphine
Prior art date
Application number
CY20151100674T
Other languages
English (en)
Inventor
Thomas Hille
Michael Horstmann
Walter Müller
Original Assignee
Lts Lohmann Therapie-Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Ag filed Critical Lts Lohmann Therapie-Systeme Ag
Publication of CY1118154T1 publication Critical patent/CY1118154T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ένα διαδερμικό θεραπευτικό σύστημα για χορήγηση της δραστικής ουσίας βουπρενορφίνη με τουλάχιστον ένα καρβοξυλικό οξύ, το οποίο καθορίζει τη διαλυτότητα της βουπρενορφίνης στην στοιβάδα μήτρας και είναι επίσης απορροφήσιμο, για την θεραπεία του άλγους με σημαντικά αυξημένη εκμετάλλευση της δραστικής ουσίας.
CY20151100674T 2006-11-21 2015-08-03 Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη CY1118154T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006054731A DE102006054731B4 (de) 2006-11-21 2006-11-21 Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP07846537.4A EP2094249B1 (de) 2006-11-21 2007-11-07 Transdermales therapeutisches system zur verabreichung des wirkstoffs buprenorphin

Publications (1)

Publication Number Publication Date
CY1118154T1 true CY1118154T1 (el) 2017-06-28

Family

ID=39326133

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151100674T CY1118154T1 (el) 2006-11-21 2015-08-03 Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη
CY20161100649T CY1117770T1 (el) 2006-11-21 2016-07-11 Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161100649T CY1117770T1 (el) 2006-11-21 2016-07-11 Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη

Country Status (25)

Country Link
US (5) US9308202B2 (el)
EP (2) EP2769714B1 (el)
JP (2) JP5763296B2 (el)
KR (1) KR101444967B1 (el)
CN (1) CN101528207B (el)
AR (1) AR064268A1 (el)
AU (1) AU2007323387B2 (el)
BR (1) BRPI0719115B8 (el)
CA (1) CA2670290C (el)
CY (2) CY1118154T1 (el)
DE (1) DE102006054731B4 (el)
DK (2) DK2094249T3 (el)
ES (2) ES2581574T3 (el)
HU (2) HUE026978T2 (el)
IL (2) IL198743A (el)
IN (1) IN2009CN02662A (el)
MX (2) MX344241B (el)
NZ (1) NZ575500A (el)
PL (2) PL2094249T3 (el)
PT (1) PT2769714E (el)
RU (1) RU2484822C2 (el)
SI (2) SI2094249T1 (el)
TW (1) TWI411452B (el)
WO (1) WO2008061625A2 (el)
ZA (1) ZA200901695B (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
RS54173B1 (sr) * 2010-12-14 2015-12-31 Acino Ag Transdermalni terapijski sistem za davanje aktivne supstance
DE102011076653A1 (de) * 2011-05-27 2012-11-29 Acino Ag Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
TW201338813A (zh) * 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts 經皮遞送系統
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104736176B (zh) * 2012-08-24 2017-10-13 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2015008021A (es) * 2012-12-21 2016-03-04 Teikoku Pharma Usa Inc Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103893154A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 包含丁丙诺啡的透皮给药系统
US11547676B2 (en) 2012-12-28 2023-01-10 Teikoku Seiyaku Co., Ltd. Extended buprenorphine transdermal delivery compositions and methods for using the same
CN108327400B (zh) * 2013-03-01 2020-02-21 松下知识产权经营株式会社 转印装置以及印刷装置
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
AU2014276910B2 (en) * 2013-06-04 2017-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
ES2703623T3 (es) * 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
EP2921184A1 (de) * 2014-03-19 2015-09-23 LTS LOHMANN Therapie-Systeme AG Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
CA2948219C (en) 2014-05-20 2023-04-04 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA3104099A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2018526415A (ja) * 2015-09-14 2018-09-13 アムニール ファーマシューティカルズ エルエルシー 経皮送達システム
AR102214A1 (es) * 2015-10-08 2017-02-15 Amarin Tech S A Un dispositivo para la administración transdermal de buprenorfina
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3074636C (en) * 2017-09-04 2024-04-30 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an emulsifier
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
BR112020018300A2 (pt) * 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
FI3854388T3 (fi) * 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermaalinen hoitojärjestelmä, jossa on vaikuttava aine rotigotiini ja ainakin yksi ei-amiiniresistentti silikoniliima
JP7173415B2 (ja) * 2020-08-19 2022-11-16 東洋インキＳｃホールディングス株式会社 貼付剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
DE3939376C1 (el) 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
DE19958554C2 (de) * 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
PL197492B1 (pl) 1999-07-02 2008-04-30 Lohmann Therapie Syst Lts Transdermalny system terapeutyczny zawierający warstwę polimerową z zawartymi w niej mikrozbiornikami i sposób wytwarzania błon
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (en) 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
ES2290512T3 (es) * 2002-08-09 2008-02-16 Grunenthal Gmbh Antagonistas del receptor opioide en sistemas transdermicos que contienen buprenorfina.
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
MXPA05006334A (es) 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
TW201338813A (zh) 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts 經皮遞送系統
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
AU2014276910B2 (en) 2013-06-04 2017-03-09 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system

Also Published As

Publication number Publication date
TWI411452B (zh) 2013-10-11
US20160175447A1 (en) 2016-06-23
BRPI0719115A2 (pt) 2013-12-10
HK1200373A1 (en) 2015-08-07
CN101528207A (zh) 2009-09-09
ES2543977T3 (es) 2015-08-26
EP2094249B1 (de) 2016-04-13
HK1132921A1 (en) 2010-03-12
HUE028971T2 (en) 2017-01-30
US20170224676A1 (en) 2017-08-10
DE102006054731B4 (de) 2013-02-28
NZ575500A (en) 2011-12-22
US20100119585A1 (en) 2010-05-13
PT2769714E (pt) 2015-08-05
BRPI0719115B1 (pt) 2019-04-24
ES2581574T3 (es) 2016-09-06
TW200836776A (en) 2008-09-16
CA2670290C (en) 2016-05-31
DK2769714T3 (en) 2015-08-03
AR064268A1 (es) 2009-03-25
US20190192506A1 (en) 2019-06-27
US9308202B2 (en) 2016-04-12
AU2007323387B2 (en) 2014-01-09
IL245290A0 (en) 2016-06-30
PL2769714T3 (pl) 2015-12-31
JP2010510259A (ja) 2010-04-02
DK2094249T3 (en) 2016-08-01
EP2769714A1 (de) 2014-08-27
HUE026978T2 (en) 2016-08-29
RU2484822C2 (ru) 2013-06-20
AU2007323387A1 (en) 2008-05-29
SI2094249T1 (sl) 2016-07-29
WO2008061625A2 (de) 2008-05-29
PL2094249T3 (pl) 2017-11-30
JP2014028844A (ja) 2014-02-13
KR20090082410A (ko) 2009-07-30
JP5882970B2 (ja) 2016-03-09
JP5763296B2 (ja) 2015-08-12
US20180289698A1 (en) 2018-10-11
IL198743A (en) 2016-05-31
IN2009CN02662A (el) 2015-08-07
EP2769714B1 (de) 2015-05-06
RU2009123368A (ru) 2010-12-27
BRPI0719115B8 (pt) 2021-05-25
ZA200901695B (en) 2009-12-30
CY1117770T1 (el) 2017-05-17
WO2008061625A3 (de) 2008-09-18
KR101444967B1 (ko) 2014-09-26
IL198743A0 (en) 2010-02-17
CN101528207B (zh) 2012-12-26
DE102006054731A1 (de) 2008-05-29
MX2009005341A (es) 2009-06-01
EP2094249A2 (de) 2009-09-02
SI2769714T1 (sl) 2015-09-30
MX344241B (es) 2016-12-07
CA2670290A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
CY1117770T1 (el) Διαδερμικο θεραπευτικο συστημα για χορηγηση της δραστικης ουσιας βουπρενορφινη
CY1120283T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης
CY1123712T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
CY1119059T1 (el) Χρηση προφαρμακων κανναβιδιολης σε τοπικη και διαδερμικη χορηγηση με μικροβελονες
MX376862B (es) Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
CY1115104T1 (el) Φαρμακα και μεθοδοι για την θεραπευτικη αγωγη της κεφαλαλγιας
CY1118281T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες συμπεριλαμβανουν υδροχλωρικη λιδοκαϊνη
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
EA201201657A1 (ru) Лечение диабета
BRPI0909557A2 (pt) conjunto de bandagem, sistema de tratamento com pressão reduzida e sistema para auxiliar a cura de um ferimento em uma paciente.
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
CY1116925T1 (el) Ρελαξινη για χρηση στη θεραπευτικη αγωγη της δυσπνοιας η οποια συσχετιζεται με οξεια καρδιακη ανεπαρκεια
CY1106834T1 (el) Διαδερμικο επιθεμα για τη χορηγηση φεντανιλ
MX2009010000A (es) Dispositivo para el suministro de farmaco.
EA201170592A1 (ru) Комбинированная терапия с применением пептид эпоксикетонов
EA201591124A1 (ru) Трансдермальная система доставки
CY1116485T1 (el) Χρηση ουλιπρισταλης στην αγωγη εναντι ινομυωματων της μητρας
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
CY1113575T1 (el) Χρηση συνθεσεων οπιοειδων σε συσκευες χορηγησης δραστικης ουσιας χωρις βελονα
MX2009011900A (es) Curacion de herida diabetica.
CY1108991T1 (el) Μεθοδος επουλωσης τραυματων με τη χορηγηση ανθρωπινης il-18
BR112012014107B8 (pt) sistema terapêutico transdérmico (tts) e processo de produção de tts
BR112013024863A2 (pt) formulação injetável de liberação sustentada
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα